Edesa Biotech, Inc. · NASDAQ:EDSA

Edesa Biotech — Investor Presentation (November 2021)

36 slides from Edesa Biotech's investor presentation, November 2021

  1. Slide 1: Corporate Presentation

    Corporate Presentation Edesa Biotech, Inc. November 2021 Nasdaq: EDSA

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such a

  3. Slide 3: Key Investment Highlights

    Key Investment Highlights Multiple clinical stage assets Validated technology Novel MOA approaches; biologics Recipient of federal Strategic Innovation and small molecule Fund reimbursement grant Sector Immune modulation Biotechnology Strong financial backing therapies and Headquarters inflammatory

  4. Slide 4: Technology Acquisition and Targeting

    Technology Acquisition and Targeting Identify overlooked clinical assets with promising growth potential Edesa’s product development strategy is focused primarily on later-stage assets Well Understood Unique Targets Novel Data-Driven Pathway on Pathway Method of Action Indication Priority  Arachido

  5. Slide 5: Edesa Development Pipeline

    Edesa Development Pipeline Advancing and Expanding Our Growth Opportunities Drug Indications Pre-Clinical Phase 1 Phase 2 Phase 3 Status/Milestones Candidates EB01 Allergic Contact Positive Blinded Interim sPLA2 Inhibitor Dermatitis Results; Enrollment Ongoing Positive Ph2 Results; EB05 ARDS and Ide

  6. Slide 6: Acute Respiratory Distress Syndrome

    Acute Respiratory Distress Syndrome EB05 Monoclonal Antibody Therapy Phase 2/3

  7. Slide 7: Strategic Innovation Fund Award

    Strategic Innovation Fund Award Validation of Edesa’s EB05 Technology  C$14 million (US$11m) reimbursement grant awarded by the Canadian Govt.  Following highly competitive, multi-disciplinary review of our plans and technology  Funding for Phase 2 portion of Phase 2/3 study of EB05  Reimburseme

  8. Slide 8: Acute Respiratory Distress Syndrome (ARDS)

    Acute Respiratory Distress Syndrome (ARDS) Leading Cause of Death in COVID-19 Patients  A life-threatening form of respiratory failure  Exaggerated immune response  Inflammation and injury to the lungs  Edema that deprives the body of oxygen  Other causes  Sepsis, bacterial and viral infection

  9. Slide 9: EB05 – Scientific Rationale

    EB05 – Scientific Rationale A Potential First-in-Class TLR-4 Pathway Inhibitor  Therapeutic target  EB05 is a monoclonal antibody that blocks TLR4 signaling PAMPs/DAMPs  TLR4 is a key mediator of innate immune response – Activated by pathogen or damage associated patterns (PAMPs & DAMPs) incl. th

  10. Slide 10: TLR4 in Severe COVID-19

    TLR4 in Severe COVID-19 Levels of TLR4 are Elevated in Severe COVID-19 Disease Key Role of Toll-like Receptor 4 TLR4 Upregulated in COVID-19 Lung Tissue*  Part of the innate immune response  Receptor for oxidized phospholipids, calprotectins and high-mobility group proteins  A Nobel prize was awa

  11. Slide 11: Evidence of Activity in Humans

    Evidence of Activity in Humans EB05 Inhibited “Cytokine Storm” after In Vivo LPS Challenge IL-6 Serum Concentration (pg/mL) TNF-α Serum Concentration (pg/mL) CXCL10 Serum Concentration (pg/mL) 250 9000 1200 8000 1000 200 7000 CXCL10 (pg/ml) 6000 TNFα (pg/ml) 800 150 IL6 (pg/ml) 5000 600 4000 100 300

  12. Slide 12: EB05 – International Phase 2/3 Clinical Study

    EB05 – International Phase 2/3 Clinical Study Phase 2 Identified Strong Mortality Benefit in Critical Patients Efficacy of EB05 in Subjects Phase 2 – Preemptively unblinded by independent monitoring board  Hospitalized with COVID-19 Infection  Strong efficacy signal for 28-day mortality  Favorabl

  13. Slide 13: Baseline Characteristics – Critically ill

    Baseline Characteristics – Critically ill ECMO and/or IMV with Additional Organ Support (Level 7), and Mild-to-Severe ARDS % of Patients by Treatment Modality Mean Age 46 IMV + Org Supp Age Range 24-62 15% BMI (mean) 36 Intent to Treat Population Non-White 30% (ITT) ECMO Corticosteroid >90% 85% IL-6

  14. Slide 14: Mortality as an Endpoint

    Mortality as an Endpoint Benchmarking Against Current Treatments Tocilizumab1 Dexamethasone2 EB05 IMV+ Maximum Severity IMV IMV and/or ECMO Mortality (Active) 31% 29% 14.3% Mortality (Placebo) 35% 41% 36.8% Number of Patients Required to Detect Signal ~4,000 ~1,000 33 Hazard Ratio 1.17 1.56 3.17 EB0

  15. Slide 15: Allergic Contact Dermatitis

    Allergic Contact Dermatitis EB01 sPLA2 Inhibitor Phase 2b

  16. Slide 16: Allergic Contact Dermatitis

    Allergic Contact Dermatitis Disease State and Current Treatments Allergic Contact Dermatitis (ACD) is a Type IV hypersensitivity reaction Current Limited Treatment Approaches for ACD Safety Issues Often Result in Discontinuation of Treatment  Immune system sensitized with initial contact with aller

  17. Slide 17: Contact Dermatitis

    Contact Dermatitis One of the most prevalent skin conditions in U.S. Claims-Based Prevalence of Skin Disease in the U.S. 9.0% 8.0%  A leading occupational illness  Affecting 13.2 million people in U.S. 7.0%  Cost of up to ~$2 billion annually 6.0%  ACD represents a submarket of contact dermatiti

  18. Slide 18: Occupational Contact Dermatitis

    Occupational Contact Dermatitis Adversely Impacts Both Employers and Employees Industry Substances  Loss of Productivity  Physical and emotional distress Agriculture Daffodils, tulips, carrots, parsnips, parsley, celery  Multiple physician visits Chemical Adhesives, paints, acrylates, acids/bases

  19. Slide 19: Novel Approaches to Chronic Conditions

    Novel Approaches to Chronic Conditions Treating Inflammation without the Safety Concerns of Current Therapies  Inhibiting the Inflammation Cascade  sPLA2 inhibitors are designed to inhibit the inflammatory process at its inception  Exerts its anti-inflammatory activity upstream of currently appro

  20. Slide 20: EB01 Efficacy in Humans Established

    EB01 Efficacy in Humans Established Phase 2 Study Demonstrated Efficacy & Safety in ACD Patients Mean Percent Improvement from Baseline in Total CDSI Score Phase 2 Efficacy Study of EB01 60 55.73% For the treatment of allergic contact dermatitis (30 Patients Bilateral Design) 50 48.62% Efficacy At D

  21. Slide 21: Phase 2 Efficacy Study – Breakdown by Component

    Phase 2 Efficacy Study – Breakdown by Component EB01 Addressed All Aspects of CDSI Composite Score Percent Reduction in Symptoms from Baseline to Day 21* P Value = <0.001 81% P Value = <0.001 62% P Value = <0.001 P Value = <0.001 P Value = <0.001 48% 47% 46% 45% 25% 20% 20% 15% Scaling Redness Pruri

  22. Slide 22: Ongoing EB01 Phase 2b Study

    Ongoing EB01 Phase 2b Study Meaningful early signals for CDSI & ISGA interim endpoints Blinded Interim Results of Phase 2b Study Patients with ACD Part A in Chronic ACD Patients* N=36 Subjects Evaluated; Randomized (1:1) Protocol (N=36)  Double blind, placebo controlled  ~1.7x difference between t

  23. Slide 23: Market Survey Reinforces Edesa’s Approach

    Market Survey Reinforces Edesa’s Approach Physicians Most Impressed with Non-Steroidal Method of Action Physician-Perceived Strengths of EB01  Key opinion leaders expressed a high desire for additional treatment options for Non-Steroidal Method of Action Novel anti-inflammatory product(MoA) (MoA) 4

  24. Slide 24: Hemorrhoids Disease

    Hemorrhoids Disease EB02 sPLA2 Inhibitor Phase 2 Ready

  25. Slide 25: Hemorrhoids Disease (HD)

    Hemorrhoids Disease (HD) Extension of sPLA2 Anti-Inflammatory Tech Treatments of Internal Hemorrhoids2  12.5 million adults affected in U.S.1 Based on their Severity and Degree of Prolapse  By 50 years old, ~50% have Grade 1 Grade 2 Grade 3 Grade 4 Complicated experienced symptomatic hemorrhoids 

  26. Slide 26: EB02 Program

    EB02 Program Targeting clinical relief of itching, pain and thrombosis of HD  Multifactorial etiology of HD  Inflammation involving the vascular wall and surrounding connective tissue  Hyper-perfusion of hemorrhoid plexus  Prolapse  Hemorrhoidal tissue contains  Inflammatory cells and  Newly

  27. Slide 27: EB02 Proof of Concept Phase 2a Study Plan

    EB02 Proof of Concept Phase 2a Study Plan Efficacy of EB02 Cream in Subjects with Protocol Grade I, II or III Internal Hemorrhoids  EB02 will be evaluated in a randomized, double-blind, placebo- controlled, two stage design. Patients with HD EB02 2.0% (n=24) Stage 1  Patients will be treated for 1

  28. Slide 28: Vitiligo and Other Autoimmune Diseases

    Vitiligo and Other Autoimmune Diseases Producing mAbs for Novel Targets

  29. Slide 29: Vitiligo and Other Autoimmune Diseases

    Vitiligo and Other Autoimmune Diseases Developing Immunotherapies for Novel Targets  Vitiligo prevalence: ~1% globally across most racial groups1 Vitiligo is a disorder in which the immune system Not merely cosmetic: chronic organ-specific  attacks and destroys melanocytes in the skin autoimmune d

  30. Slide 30: Corporate Highlights

    Corporate Highlights Milestones Financial Summary Capitalization Leadership

  31. Slide 31: Recent Highlights, Milestones & Strategic Objectives

    Recent Highlights, Milestones & Strategic Objectives PHASE 2/3 COVID-19 STUDY STRATEGIC TRANSACTION & IND & CTA approval DEVELOP NEW MARKETS CAPITALIZATION Manufacturing of drug product Vitiligo project initiation Reverse acquisition / Nasdaq listing Initiate sub-study for critically severe patients

  32. Slide 32: Cash Position

    Cash Position Balance sheet Selected Financials As of June 30, 2021  Working capital focused on clinical programs Working Capital $ 13.4 M  $11 million (C$14m) reimbursement grant Cash & Cash Equiv. $ 8.1 M from federal Strategic Innovation Fund  $10m equity offering – March 2021 Total Assets $ 1

  33. Slide 33: Capitalization Table

    Capitalization Table As of August 2021 Common Shares and Weighted Average Description Common Share Exercise Price Equivalents Common Shares 13,255,559 Options Outstanding* $5.07 1,772,719 Warrants $5.65 760,290 Fully Diluted Shares 15,788,568 * 2019 Equity Incentive Compensation Plan 33

  34. Slide 34: Holders of Common Shares

    Holders of Common Shares Simplified Beneficial Ownership Table as of August 2021 Percent Shares Percent Holders Shares Outstanding Share Options Warrant Shares Fully Diluted Early Series Financing from Life Science Directors and Officers Specialists Par Nijhawan 3,271,785 24.7% 229,110 6,942 22.2% L

  35. Slide 35: Experienced Leadership Team

    Experienced Leadership Team Pharmaceutical Pipelines, Corporate Development & Strategic Transactions Senior Management Team Par Nijhawan, MD, FRCPC, AGAF Board-certified gastroenterologist and hepatologist • Successful track record of building life science businesses, including CEO and Board Directo

  36. Slide 36: Company Contacts

    Company Contacts Par Nijhawan Chief Executive Officer Michael Brooks President Gary Koppenjan Investor Relations Edesa Biotech, Inc. 100 Spy Court Markham, Ontario L3R 5H6 +1 (289) 800-9600 investors@edesabiotech.com www.EdesaBiotech.com

Edesa Biotech — Investor Presentation (November 2021) on 6ix